STENOCARE A/S has been declared IPO of the Year 2018

Last night, at a ceremony in Stockholm, STENOCARE was revealed as the winner of the SvD Börsplus IPO-guide award IPO of the Year 2018 in the category Quality. STENOCARE was also awarded the honorary prize in the category Value growth.

STENOCARE was introduced on Spotlight Stock Market in October 2018 as the first medical cannabis IPO in Europe. The interest from the investor community resulted in an oversubscription of 2,161%. Since the IPO, the company has successfully met critical milestones and even overperformed on their sales of medical cannabis oil products to Danish patients.

The award is hosted by SvD Börsplus, a part of Svenska Dagbladet, which is a leading news media in Sweden. SvD Börsplus evaluate all IPOs during the year from an investor point of view – with the objective to praise and highlight quality. The award is divided into two different categories, quality and value growth, and are granted to companies in the large cap-, small cap- and micro segments.

A total of 29 companies competed in the micro segment and STENOCARE was awarded Best IPO 2018 in the category “Quality”, based on its strong value growth and zero “warning flags” across 24 indicators. STENOCARE was also awarded the honorary prize in the category “Value growth”, with a share price development of 205% relative to the OMXS30 index.

Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:

“We are honored and humbled with this IPO of the Year 2018 award. It took a lot of hard work to prepare and execute. The award is a huge kudos to the entire STENOCARE team and our advisors from Sedermera Fondkommission, Gemstone Capital and Spotlight Stock Market”.


For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO         

Phone: +45 31770060

E-mail: presse@stenocare.com

About STENOCARE A/S

STENOCARE A/S was founded in 2017 with the purpose of being an active participant in the Danish medical cannabis pilot program. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. The company offers medical cannabis oil that comply with the strict Danish regulatory requirements. STENOCARE is also developing a separate production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.

Tags:

About Us

STENOCARE A/S is founded in 2017 to work with the Danish legalization program for medical cannabis to give better quality of life for patients. The company import’s and sell finished products for the Danish market via distributors. STENOCARE has approvals from the Danish Medicine Agency to supply pharmacies and hospitals with medical cannabis oil products. The company will build a production facility to cultivate and manufacture their own finished medical cannabis products for patients in Denmark and Europe, and thereby command the entire value chain and secure supply capacity. STENOCARE has a strategic partner, CannTrust Inc, that is providing their technology and knowhow for production of medical cannabis.